Folger Hill Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Folger Hill Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-7,531	Closed	-$601K	–	177
2017 Q2	$601K	Sell	7,531 -3,980	-35%	-$254K	0.05%	191
2017 Q1	$590K	Buy	+11,511	New	+$532K	0.05%	217

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Folger Hill Asset Management's ALNY Position: Q3 2017 in Review

Folger Hill Asset Management sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2017, closing a stake of 7,531 shares — an estimated $601K sold.

Folger Hill Asset Management first reported a position in ALNY in Q1 2017 and held it in 2 quarters. The position peaked at $601K in Q2 2017. 236 funds tracked by Wall St. Rank hold ALNY as of Q3 2017.

Folger Hill Asset Management reported no remaining Alnylam Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Folger Hill Asset Management sold 7,531 Alnylam Pharmaceuticals shares in Q3 2017, an estimated $601K.
Folger Hill Asset Management first reported a position in Alnylam Pharmaceuticals in Q1 2017 and held it in 2 quarters.
Folger Hill Asset Management's Alnylam Pharmaceuticals position peaked at $601K in Q2 2017.
236 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2017.

Based on Folger Hill Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.